Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Non-Current Deffered Revenue: 2018-2023

  • RedHill Biopharma's Non-Current Deffered Revenue fell 28.00% to $540,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $540,000, marking a year-over-year decrease of 28.00%. This contributed to the annual value of $540,000 for FY2023, which is 28.00% down from last year.
  • According to the latest figures from Q4 2023, RedHill Biopharma's Non-Current Deffered Revenue is $540,000, which was down 28.00% from $750,000 recorded in Q4 2022.
  • Over the past 5 years, RedHill Biopharma's Non-Current Deffered Revenue peaked at $750,000 during Q4 2020, and registered a low of $500,000 during Q4 2019.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $750,000 (2022), whereas its average is $680,000.
  • Per our database at Business Quant, RedHill Biopharma's Non-Current Deffered Revenue skyrocketed by 50.00% in 2020 and then dropped by 28.00% in 2023.
  • Quarterly analysis of 5 years shows RedHill Biopharma's Non-Current Deffered Revenue stood at $500,000 in 2019, then soared by 50.00% to $750,000 in 2020, then remained steady at $750,000 in 2021, then remained steady at $750,000 in 2022, then fell by 28.00% to $540,000 in 2023.
  • Its last three reported values are $540,000 in Q4 2023, $750,000 for Q4 2022, and $750,000 during Q4 2021.